Compare Cassava Sciences Inc (FLNA) vs Meta Platforms Inc (META) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

META stock trades at $661.04, up 0.66% today, with a bullish technical signal driven by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected, and maintains robust profitability with a 32.84% net income margin. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though it faces a youth addiction lawsuit in Massachusetts.

The outlook remains positive with a consensus price target of $815.44, implying 23% upside, supported by 79% analyst buy ratings. Key risks include regulatory lawsuits and high capital expenditure for AI investments. Revenue growth is projected to reach $215.0 billion in 2026, with net income rising to $70.6 billion, reinforcing its strong fundamental position.